Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study
2019/05/21 by Vanina Popova, Ella Daly, Ella J. Daly +17 · 32 citations
Medicine · Psychology · #Treatment of Major Depression #Psychedelics and Drug Studies #Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
paper · pdf · doi:10.1176/appi.ajp.2019.19020172
Abstract
OBJECTIVE: About one-third of patients with depression fail to achieve remission despite treatment with multiple antidepressants. This study compared the efficacy and safety of switching patients with treatment-resistant depression from an ineffective antidepressant to flexibly dosed esketamine nasal spray plus a newly initiated antidepressant or to a newly initiated antidepressant (active comparator) plus placebo nasal spray. METHODS: This was a phase 3, double-blind, active-controlled, multicenter study conducted at 39 outpatient referral centers. The study enrolled adults with moderate to severe nonpsychotic depression and a history of nonresponse to at least two antidepressants in the current episode, with one antidepressant assessed prospectively. Confirmed nonresponders were randomly assigned to treatment with esketamine nasal spray (56 or 84 mg twice weekly) and an antidepressant or antidepressant and placebo nasal spray. The primary efficacy endpoint, change from baseline to day 28 in Montgomery-Åsberg Depression Rating Scale (MADRS) score, was assessed by a mixed-effects model using repeated measures. RESULTS: Of 435 patients screened, 227 underwent randomization and 197 completed the 28-day double-blind treatment phase. Change in MADRS score with esketamine plus antidepressant was significantly greater than with antidepressant plus placebo at day 28 (difference of least square means=-4.0, SE=1.69, 95% CI=-7.31, -0.64); likewise, clinically meaningful improvement was observed in the esketamine plus antidepressant arm at earlier time points. The five most common adverse events (dissociation, nausea, vertigo, dysgeusia, and dizziness) all were observed more frequently in the esketamine plus antidepressant arm than in the antidepressant plus placebo arm; 7% and 0.9% of patients in the respective treatment groups discontinued study drug because of an adverse event. Adverse events in the esketamine plus antidepressant arm generally appeared shortly after dosing and resolved by 1.5 hours after dosing. CONCLUSIONS: Current treatment options for treatment-resistant depression have considerable limitations in terms of efficacy and patient acceptability. Esketamine is expected to address an unmet medical need in this population through its novel mechanism of action and rapid onset of antidepressant efficacy. The study supports the efficacy and safety of esketamine nasal spray as a rapidly acting antidepressant for patients with treatment-resistant depression.
Cited by
- Fluoroethylnormemantine, a Novel NMDA Receptor Antagonist, for the Prevention and Treatment of Stress-Induced Maladaptive Behavior
- Ketamine and Esketamine in Clinical Trials: <scp>FDA‐</scp>Approved and Emerging Indications, Trial Trends With Putative Mechanistic Explanations
- Quality of life and productivity among esketamine responders in a real-world study in Australia and New Zealand
- Ketamine reduces the neural distinction between self- and other-produced affective touch: a randomized double-blind placebo-controlled study
- Ketamine and rapid antidepressant action: new treatments and novel synaptic signaling mechanisms
- Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Plus a Newly Initiated Oral Antidepressant in Adult Patients with Treatment-Resistant Depression: A Randomized, Double-Blind, Multicenter, Active-Controlled Study Conducted in China and USA
- Intranasal esketamine in treatment-resistant depression with and without comorbid borderline personality disorder: A multicenter real-world longitudinal study
- The “Africanisation” of communication studies
- Ketamine and depression: a narrative review. [europepmc]
- Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression. [europepmc]
- Efficacy of single and repeated administration of ketamine in unipolar and bipolar depression: a meta-analysis of randomized clinical trials. [europepmc]
- Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers. [europepmc]
- Pharmacological Treatments for Patients with Treatment-Resistant Depression. [europepmc]
- A randomized, double-blind, active placebo-controlled study of efficacy, safety, and durability of repeated vs single subanesthetic ketamine for treatment-resistant depression. [europepmc]
- Esketamine: new hope for the treatment of treatment-resistant depression? A narrative review. [europepmc]
- Advances in the field of intranasal oxytocin research: lessons learned and future directions for clinical research. [europepmc]
- Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis. [europepmc]
- The role of dissociation in ketamine's antidepressant effects. [europepmc]
- A Dendrite-Focused Framework for Understanding the Actions of Ketamine and Psychedelics. [europepmc]
- Major Depressive Disorder: Advances in Neuroscience Research and Translational Applications. [europepmc]
- Ketamine-50 years in use: from anesthesia to rapid antidepressant effects and neurobiological mechanisms. [europepmc]
- Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation. [europepmc]
- Efficacy and Tolerability of Combination Treatments for Major Depression: Antidepressants plus Second-Generation Antipsychotics vs. Esketamine vs. Lithium. [europepmc]
- Ventromedial prefrontal cortex/anterior cingulate cortex Glx, glutamate, and GABA levels in medication-free major depressive disorder. [europepmc]
- Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder. [europepmc]
- Augmentative Pharmacological Strategies in Treatment-Resistant Major Depression: A Comprehensive Review. [europepmc]
- Ketamine treatment for depression: a review. [europepmc]
- Expectancy in placebo-controlled trials of psychedelics: if so, so what? [europepmc]
- New and emerging approaches to treat psychiatric disorders. [europepmc]
- Intranasal Polymeric and Lipid-Based Nanocarriers for CNS Drug Delivery. [europepmc]
- The antidepressant actions of ketamine and its enantiomers. [europepmc]
- Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study. [europepmc]
- Ketamine in neuropsychiatric disorders: an update. [europepmc]
Related